Clinical Trials Browser

INDUSTRY × lanreotide × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00353496 2025-03-05

CLARINET

Phase 3 Completed

264 enrolled 17 charts

Endocrine Tumors

NCT00774930 2022-10-14

ELECT

Phase 3 Completed

115 enrolled 17 charts

EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00842348 2022-10-12

NET729

Phase 3 Completed

89 enrolled 9 charts

EndocrineNET

Neuroendocrine Tumors

NCT02683941 2022-07-06

SPINET

Phase 3 Terminated

77 enrolled 20 charts

EndocrineNET

Neuroendocrine Tumors in Lung

NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Phase 3 Completed

80 enrolled

Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

NCT00326469 2020-11-05

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Phase 2 Completed

30 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02698410 2020-10-01

ATLANT

Phase 2 Completed

40 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT00681187 2019-11-22

SAPHE

Phase 4 Completed

26 enrolled 18 charts

Endocrine

Neuroendocrine Tumour With Carcinoid Symptoms

NCT01313273 2019-11-22

POSEIDON

Phase 3 Terminated

3 enrolled 4 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

ACTION-1

CLARINET

ELECT

NET729

SPINET

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

ATLANT

SAPHE

POSEIDON